[Lu-177]-PNT3090 / Eli Lilly - LARVOL DELTA

Pre-clinical development of next-generation FAP-targeting radioligands with improved tumor retention (SNMMI 2025) - "PNT3087, PNT3090, and PNT3106 demonstrated higher affinity and improved tumor retention relative to other FAP-targeting radioligands (PNT6555 and DOTAGA.SA(FAPi)2) in preclinical settings. Human dosimetry estimates predict a favorable safety profile. Together, these data support further evaluation of the candidate ligands in the clinic."

Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • CAFs • FAP

Pre-clinical development of next-generation FAP-targeting radioligands with improved tumor retention (SNMMI 2025) - "PNT3087, PNT3090, and PNT3106 demonstrated higher affinity and improved tumor retention relative to other FAP-targeting radioligands (PNT6555 and DOTAGA.SA(FAPi)2) in preclinical settings. Human dosimetry estimates predict a favorable safety profile. Together, these data support further evaluation of the candidate ligands in the clinic."

Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • CAFs • FAP

Next generation Fibroblast Activation Protein (FAP)-Targeted Lutetium 177 labelled radioligands - Clinical application of subtherapeutic activity (SNMMI 2025) - "Subtherapeutic activity of [Lu-177]-PNT3087, [Lu-177]-PNT3090, and [Lu-177]-PNT3106 were well-tolerated and showed substantially improved retention in FAP-positive metastatic breast cancer pts compared to first generation FAP-ligands. Together, these data support the continued investigation of these radioligands for clinical development. Juneau D, et al."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • FAP • HER-2